{"product_id":"met-antibody-sc-f1377","title":"Phospho-Met (Tyr1003) Antibody","description":"\u003ch2\u003eAbout the Target\u003c\/h2\u003e\u003cp\u003ePhospho-MET (Tyr1003) refers to the hepatocyte growth factor receptor (MET) phosphorylated at tyrosine residue 1003, a key regulatory site within the juxtamembrane domain of the receptor. MET is a class IV receptor tyrosine kinase encoded by the MET gene on chromosome 7q21-31 and is expressed predominantly on the surface of epithelial cells. Depending on the literature source, MET may also be discussed as Phospho-Met (Tyr1003) and c-met.\u003c\/p\u003e\u003cp\u003eReported cellular context includes membrane and secreted, which can matter when signal is compared across treatments or changing cell states. Following MET across matched perturbations can help separate abundance effects from shifts in localization, complex assembly, or pathway state.\u003c\/p\u003e\u003ch2\u003eResearch Context\u003c\/h2\u003e\u003cp\u003eMET is commonly interpreted in the context of cancer and cell signaling research, and readouts are often stronger when a study separates expression changes from compartment-level redistribution. When reported signal spans membrane and secreted, a defined reference condition can make comparisons more interpretable across perturbations, passages, or replicate sets.\u003c\/p\u003e\u003cp\u003eConsider these angles when interpreting target-level changes:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eapparent redistribution between membrane and secreted across matched conditions\u003c\/li\u003e\n\u003cli\u003echanges associated with proliferative state, oncogenic signaling, or treatment response\u003c\/li\u003e\n\u003cli\u003esignal-dependent shifts after ligand, inhibitor, or growth-factor perturbation\u003c\/li\u003e\n\u003cli\u003edifferences between total target abundance and site-specific regulation when modified forms are compared\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eVariant Considerations\u003c\/h2\u003e\u003cp\u003eIf your project spans exploratory questions, the regular version offers a balanced option for establishing baseline signal behavior for MET. This can help when protocols evolve over time and the goal is to compare experiments using a stable reference workflow.\u003c\/p\u003e\u003cp\u003eStandardize sampling time, control choice, and downstream analysis thresholds so apparent differences in MET reflect biology rather than handling. When interpreting MET, it is often useful to decide early whether the main question is overall abundance, compartmental enrichment, or context-dependent redistribution.\u003c\/p\u003e\u003cp\u003eFor multi-run studies, a shared reference condition can keep MET trends easier to compare across datasets. That kind of consistency is especially helpful when follow-up work expands to new perturbations, model systems, or longitudinal collections.\u003c\/p\u003e","brand":"Selleck Chemicals","offers":[{"title":"20 µl","offer_id":57577711960409,"sku":"F1377-20UL","price":159.0,"currency_code":"EUR","in_stock":true},{"title":"100 µl","offer_id":57577711993177,"sku":"F1377-100UL","price":389.0,"currency_code":"EUR","in_stock":true},{"title":"2 × 100 µl","offer_id":57577712025945,"sku":"F1377-2X100UL","price":589.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0923\/1011\/0553\/files\/F1377-wb.gif?v=1773599665","url":"https:\/\/absource.de\/products\/met-antibody-sc-f1377","provider":"Absource Diagnostics","version":"1.0","type":"link"}